RenovaCare, Inc. (RCAR)

0.0001 0.0000 (0.00%) At close: 11:35AM EDT

RenovaCare, Inc.

9375 East Shea Blvd
Suite 107-A
Scottsdale, AZ 85260
United States
888 398 0202
https://www.renovacareinc.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Harmel S. Rayat	President, CEO, CFO, Interim Secretary & Chairman of the Board	N/A	N/A	1961
Dr. Robin A. Robinson Ph.D.	Chairman of Scientific Advisory Board, VP & Chief Scientific Officer	220k	N/A	1956
Mr. Justin Frere CPA, M.B.A.	Treasurer	208.08k	N/A	1973
Dr. Jo Ellen Schweinle M.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.

Corporate governance

RenovaCare, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.